Reaction
Palmar Erythema reporting signals
As of the last recalculation, Palmar Erythema appears in 1,132 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is CHLORHEXIDINE GLUCONATE (PRR 45.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Chlorhexidine Gluconate | 22 | 45.1 | 45.2 |
| Regorafenib | 14 | 22.4 | 22.5 |
| Trimethoprim | 13 | 20.5 | 20.5 |
| Lapatinib | 13 | 15.6 | 15.6 |
| Pertuzumab | 20 | 13.8 | 13.8 |
| Fosaprepitant Dimeglumine | 10 | 13.5 | 13.5 |
| Carboplatin | 85 | 13.2 | 13.2 |
| Aprepitant | 13 | 13.1 | 13.1 |
| Sorafenib | 14 | 12.5 | 12.5 |
| Benzonatate | 11 | 12.3 | 12.4 |
| Pemetrexed | 14 | 12.1 | 12.2 |
| Capecitabine | 53 | 11.1 | 11.1 |
| Oxaliplatin | 43 | 11.0 | 11.0 |
| Paclitaxel (Aibumin-Bound) | 46 | 10.7 | 10.7 |
| Trastuzumab | 34 | 9.4 | 9.4 |
| Paclitaxel | 47 | 9.1 | 9.1 |
| Panitumumab | 7 | 8.3 | 8.3 |
| Pemetrexed Disodium | 15 | 7.3 | 7.3 |
| Docetaxel Anhydrous | 26 | 7.2 | 7.2 |
| Docetaxel | 26 | 7.2 | 7.2 |
| Cabozantinib | 17 | 6.6 | 6.6 |
| Lenvatinib | 11 | 6.2 | 6.2 |
| Bosutinib | 3 | 6.2 | 6.2 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 5 | 3.0 | 3.0 |